Cargando…

Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome

BACKGROUND: The lysosomal storage disorder, mucopolysaccharidosis I (MPS I), commonly manifests with upper airway obstruction and sleep disordered breathing (SDB). The success of current therapies, including haematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) may be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pal, Abhijit Ricky, Langereis, Eveline J, Saif, Muhammad A, Mercer, Jean, Church, Heather J, Tylee, Karen L, Wynn, Robert F, Wijburg, Frits A, Jones, Simon A, Bruce, Iain A, Bigger, Brian W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450482/ https://www.ncbi.nlm.nih.gov/pubmed/25887468 http://dx.doi.org/10.1186/s13023-015-0255-4

Ejemplares similares

Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy
por: Pal, Abhijit Ricky, et al.
Publicado: (2018)

Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications
por: Kuiper, Gé-Ann, et al.
Publicado: (2018)

An algorithm to predict phenotypic severity in mucopolysaccharidosis type I in the first month of life
por: Kingma, Sandra DK, et al.
Publicado: (2013)

Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I
por: Ghosh, Arunabha, et al.
Publicado: (2019)

Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome)
por: Valstar, Marlies J, et al.
Publicado: (2011)

Prediction of phenotypic severity in mucopolysaccharidosis type IIIA
por: Knottnerus, Suzan J. G., et al.
Publicado: (2017)

Assessment of Sleep in Children with Mucopolysaccharidosis Type III
por: Mahon, Louise Victoria, et al.
Publicado: (2014)

Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?
por: Horgan, Claire, et al.
Publicado: (2022)

Attitudes of relatives of mucopolysaccharidosis type III patients toward preconception expanded carrier screening
por: Nijmeijer, Stephanie C. M., et al.
Publicado: (2020)

Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure
por: Langereis, Eveline J, et al.
Publicado: (2013)

Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder
por: Wijburg, Frits A, et al.
Publicado: (2013)

Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases
por: Langford-Smith, Kia Jane, et al.
Publicado: (2010)

Treatment of thoracolumbar kyphosis in patients with mucopolysaccharidosis type I: results of an international consensus procedure
por: Kuiper, Gé-Ann, et al.
Publicado: (2019)

Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype
por: Valstar, Marlies J., et al.
Publicado: (2010)

Preconception expanded carrier screening: a focus group study with relatives of mucopolysaccharidosis type III patients and the general population
por: Conijn, Thirsa, et al.
Publicado: (2021)

Diagnosing mucopolysaccharidosis IVA
por: Wood, Timothy C., et al.
Publicado: (2013)

Respiratory and sleep disorders in mucopolysaccharidosis
por: Berger, Kenneth I., et al.
Publicado: (2012)

Female Mucopolysaccharidosis IIIA Mice Exhibit Hyperactivity and a Reduced Sense of Danger in the Open Field Test
por: Langford-Smith, Alex, et al.
Publicado: (2011)

Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry
por: D’Aco, Kristin, et al.
Publicado: (2012)

Juvenile mucopolysaccharidosis plus disease caused by a missense mutation in VPS33A
por: Pavlova, Elena V., et al.
Publicado: (2022)

Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIB
por: Wilkinson, Fiona L., et al.
Publicado: (2012)

Anaesthesia and airway management in mucopolysaccharidosis
por: Walker, Robert, et al.
Publicado: (2012)

Genotype‐phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry
por: Clarke, Lorne A., et al.
Publicado: (2019)

Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
por: Bugiani, Marianna, et al.
Publicado: (2023)

A deletion of IDUA exon 10 in a family of Golden Retriever dogs with an attenuated form of mucopolysaccharidosis type I
por: Faller, Kiterie M. E., et al.
Publicado: (2020)

Mucopolysaccharidosis I; Parental beliefs about the impact of disease on the quality of life of their children
por: Soni-Jaiswal, A., et al.
Publicado: (2016)

Heparan Sulfate Inhibits Hematopoietic Stem and Progenitor Cell Migration and Engraftment in Mucopolysaccharidosis I
por: Watson, H. Angharad, et al.
Publicado: (2014)

Airway-Related Symptoms and Surgeries in Patients With Mucopolysaccharidosis I
por: Arn, Pamela, et al.
Publicado: (2015)

Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure
por: de Ru, Minke H, et al.
Publicado: (2011)

Easy‐to‐use algorithm would provide faster diagnoses for mucopolysaccharidosis type I and enable patients to receive earlier treatment
por: Tylki‐Szymańska, Anna, et al.
Publicado: (2018)

Actigraphic investigation of circadian rhythm functioning and activity levels in children with mucopolysaccharidosis type III (Sanfilippo syndrome)
por: Mumford, Rachel A., et al.
Publicado: (2015)

Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III
por: Ghosh, Arunabha, et al.
Publicado: (2017)

An investigation of the middle and late behavioural phenotypes of Mucopolysaccharidosis Type-III
por: Cross, Elaine M, et al.
Publicado: (2014)

RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis
por: Wiesinger, Anna-Maria, et al.
Publicado: (2023)

Pre-clinical Safety and Efficacy of Lentiviral Vector-Mediated Ex Vivo Stem Cell Gene Therapy for the Treatment of Mucopolysaccharidosis IIIA
por: Ellison, Stuart M., et al.
Publicado: (2019)

Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II
por: Gleitz, Hélène F. E., et al.
Publicado: (2017)

Sleep-related hypermotor epilepsy in a patient with mucopolysaccharidosis type III
por: Abramova, Anna A., et al.
Publicado: (2021)

A Multiplex Assay for the Diagnosis of Mucopolysaccharidoses and Mucolipidoses
por: Langereis, Eveline J., et al.
Publicado: (2015)

Intraparenchymal convection enhanced delivery of AAV in sheep to treat Mucopolysaccharidosis IIIC
por: O’Leary, Claire, et al.
Publicado: (2023)

Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB
por: Meijer, O. L. M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_050duvtgipcc7mradrrh3u0tbk